Jade Biosciences (JBIO) said late Friday it has closed its public offering of 11.5 million shares, including the full exercise of an over-allotment option, raising $172.5 million for the clinical-stage biotechnology company.

The company said net proceeds will be used among others for clinical trials, preclinical studies, working capital and other general corporate purposes.